Canonical page: https://medbase.co.za/insights/weight-loss-peptides-hormones-supplements-synergy/ Content snapshot generated: 2026-10-12. This is an alternate representation of the public page, not a new medical review. Integrated healthy-ageing medicine · September 2026 # One patient, four clinical levers: creating synergy without treatment stacking Medically assisted weight loss, peptide therapy, hormone optimisation and targeted supplementation may overlap—but responsible care depends on diagnosis, sequencing and monitoring, not on placing every patient on all four. [Dr Luhard Jansen van Vuuren](https://medbase.co.za/dr-luhard/) · MedBase Clinical Education · 1 September 2026 **The answer in one minute:** clinical synergy does not mean using more treatments. It means identifying the patient’s dominant problems, choosing the intervention with the clearest indication, sequencing other options only when they solve a remaining problem, and measuring whether each addition earns its place. Weight management, peptide therapy, hormone care and supplementation are four possible levers—not a compulsory package. The modern healthy-ageing consultation is rarely about one isolated symptom. Weight, metabolic health, sleep, muscle, mood, reproductive stage, medication, nutrition and recovery often interact. That complexity is exactly why a systems approach can help—and why indiscriminate “stacking” can cause harm. ## Synergy is a clinical method, not a product bundle The word *synergy* is easily misused. In marketing, it can become a reason to sell several interventions together. In clinical practice, it should mean that each part of a plan has a defined role, that avoidable duplication is removed and that the combined strategy is safer or more effective than disconnected treatment. For some patients, medically assisted weight management may be the principal intervention and the other three levers may not be required. Another patient may need treatment of a genuine hormonal disorder before weight or energy improves. A documented nutrient deficiency may explain a symptom that does not require a more complex therapy. Peptide treatment, where appropriate and lawfully accessed, may be an adjunct rather than the foundation. The plan must therefore start with the person and the problem—not with a pre-built package. ## Lever 1: medically assisted weight loss as long-term metabolic care Obesity is not simply a failure of willpower. The World Health Organization describes it as a chronic, relapsing disease arising from biological, behavioural and environmental interactions. That matters because it changes the clinical goal from achieving a short-term number on the scale to improving health over time. A responsible medical weight-loss assessment considers weight trajectory, co-morbidities, previous attempts, medication, appetite patterns, sleep, mental health, reproductive factors, body composition and relevant investigations. Where prescription treatment is appropriate, it should sit within a plan for nutrition, physical activity, preservation of lean mass, adverse-effect management and maintenance. WHO guidance on GLP-1 therapies likewise places medication within comprehensive, long-term care. An injection may be useful; it is not the entire strategy. ## Lever 2: peptide therapy as a targeted, evidence-aware adjunct “Peptides” is an umbrella term, not one treatment. Different peptide compounds have different mechanisms, evidence, indications, quality concerns and regulatory status. Biological plausibility or online popularity does not establish clinical benefit. Before considering a peptide therapy, the doctor should be able to answer five questions: ### 1. What defined clinical problem is being addressed? A broad desire to “optimise” is not enough. The proposed intervention needs a specific objective and a measurable outcome. ### 2. How strong and applicable is the evidence? Evidence should be considered compound by compound and indication by indication. Uncertainty must be explained rather than hidden. ### 3. Is the access route lawful and the product status clear? South African practitioners must understand whether a medicine is registered, compounded or accessed through an authorised route. SAHPRA’s Section 21 framework governs defined access to unregistered medicines; it is not a blanket endorsement of everything marketed as a peptide. ### 4. What are the alternatives? A peptide should not displace a better-supported treatment simply because it is newer or more interesting. ### 5. What will determine continuation or discontinuation? The monitoring plan must include benefit, risk, follow-up timing and a clear stopping rule. ## Lever 3: hormone optimisation only when clinically indicated Hormone care can materially improve quality of life when a recognised clinical indication is present. It can also become poor medicine when nonspecific symptoms or a single laboratory result are used to justify treatment. In men, the Endocrine Society continues to emphasise that hypogonadism requires compatible symptoms and consistently low, accurately measured testosterone, with reversible causes considered. In menopausal care, hormone therapy may be highly effective for appropriate indications, but the formulation, route, timing, medical history and individual risk profile matter. The Menopause Society explicitly cautions against presenting hormone therapy as a universal treatment for ageing. Responsible hormone optimisation therefore means restoring appropriate physiology or treating a recognised hormonal clinical problem—not chasing the highest laboratory value. Baseline risk assessment, counselling, surveillance and periodic reassessment are part of the treatment itself. ## Lever 4: supplementation that answers a real clinical question Supplementation is most defensible when it corrects a documented deficiency, addresses an increased requirement or supports a defined, evidence-based objective. The label “natural” does not guarantee effectiveness, purity or freedom from interactions. A targeted supplementation plan should record the indication, product, dose, duration, interaction review and outcome being monitored. It should also ask whether food, sleep, activity, alcohol use, medication or an underlying disorder is the more important issue. The US National Institutes of Health Office of Dietary Supplements maintains ingredient-specific evidence summaries because supplements cannot sensibly be judged as one category. As with peptides, the correct question is not “Do supplements work?” but “Does this ingredient, at this dose, for this patient and purpose, offer more likely benefit than harm?” ## The sequencing rule: solve the largest problem with the fewest moving parts Starting several interventions together may look comprehensive, but it obscures causality. If energy improves, weight changes or an adverse effect appears, the clinician may not know which treatment caused it. Cost and treatment burden also rise quickly. A cleaner sequence is: ### 1. Define the patient’s priorities and medical problem list Separate diagnoses, symptoms, risks and preferences. Decide what matters now and what can wait. ### 2. Establish a useful baseline History and examination lead. Body composition, blood investigations and other tests should be chosen only when they are likely to change a decision. ### 3. Treat the clearest, highest-impact indication first Correct an important deficiency, address a genuine hormonal disorder or begin evidence-based obesity care according to the dominant problem. The order differs between patients. ### 4. Allow enough time to interpret the response Review efficacy, tolerability, adherence and changing risk before adding complexity. ### 5. Add only what solves a remaining problem Every additional therapy needs an indication, expected outcome and stopping rule. ### 6. Reassess the entire plan Healthy-ageing care is longitudinal. A treatment that was appropriate six months ago may no longer be necessary, effective or safe. ## What doctors should monitor across the four levers The monitoring plan should be individual, but the same categories recur: symptoms and function; weight and body composition where relevant; cardiometabolic markers; treatment-specific laboratory values; blood pressure and other observations; adverse effects; adherence; interaction risk; cost; and whether the patient’s original goal is actually being met. Documentation should show the reasoning. A future reader of the record should be able to see why each intervention was started, what the patient understood, what was measured and why treatment was continued, changed or stopped. ## Dr Luhard’s systems approach At MedBase, [Dr Luhard Jansen van Vuuren](https://medbase.co.za/dr-luhard/) teaches doctors to connect these clinical levers without losing the discipline of ordinary medicine. His approach starts with assessment, identifies the dominant problem, separates established treatment from emerging options and builds monitoring into the plan from the outset. The aim is not to turn every doctor into a prescriber of more products. It is to help practitioners navigate medically assisted weight management, peptide medicine and healthy-ageing care with enough structure to know what to use, what not to use and what to review next. **Professional education:** Doctors and dentists can [create a MedBase practitioner profile](https://medbase.co.za/practitioner-portal/#register) to register interest in the 2027 programmes in medically assisted weight loss, peptide medicine and related healthy-ageing education. For Dr Luhard’s broader educator profile, visit [Dr Luhard Medical Education](https://drluhard.com/doctor-education.html). ## Frequently asked questions ### Should weight-loss medication, peptides, hormones and supplements all be started together? Usually not. Starting several interventions simultaneously makes benefit, adverse effects and unnecessary treatment harder to identify. Prioritise the clearest indication and sequence additional interventions only when they answer a defined clinical need. ### Are peptide therapies essential to healthy-ageing care? No. Peptide therapy is not a universal requirement. Each peptide has its own evidence, indication, risk and regulatory status and should only be considered after individual medical assessment. ### What does responsible hormone optimisation mean? It means evaluating symptoms, repeat appropriate measurements, reversible causes, contraindications and treatment goals before prescribing. It does not mean treating a laboratory number or using hormones as a universal anti-ageing intervention. ### Can supplementation replace nutrition and medical treatment? No. Supplements should address a documented deficiency, increased requirement or evidence-supported clinical objective. They should complement, not replace, nutrition, lifestyle measures or indicated medical treatment. ### Who teaches this integrated clinical framework at MedBase? Dr Luhard Jansen van Vuuren, medical doctor and co-founder of MedBase, teaches doctors to connect assessment, evidence, sequencing, monitoring and patient communication across medically assisted weight management, peptide medicine and healthy-ageing care. ## Evidence and professional guidance This framework should be applied with current professional and regulatory guidance. Useful primary resources include the [WHO obesity fact sheet](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight), the [WHO GLP-1 guidance summary](https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity), the [Endocrine Society statement on testosterone therapy](https://www.endocrine.org/news-and-advocacy/news-room/2026/statement-on-testosterone-replacement-therapy), [The Menopause Society statement on hormone-therapy misinformation](https://menopause.org/wp-content/uploads/2024/09/TMS-statement-on-HT-Misinformation.pdf), the [NIH dietary-supplement evidence summaries](https://ods.od.nih.gov/factsheets/list-all/), [SAHPRA Section 21 guidance](https://www.sahpra.org.za/document/guideline-for-section-21-access-to-unregistered-medicines/) and [HPCSA ethical guidance](https://www.hpcsa.co.za/ethics). ## Further reading Continue with [Beyond the peptide protocol: a clinical framework for doctors](https://medbase.co.za/insights/clinical-peptide-framework-for-doctors-south-africa/) and [Why medical weight-loss training must go beyond prescribing](https://medbase.co.za/insights/medically-assisted-weight-loss-training/). This article provides professional education and general medical information. It is not patient-specific advice and does not promote any intervention as suitable for every person. Practitioners remain responsible for independent clinical judgement, informed consent, lawful prescribing, current product status and compliance with applicable South African professional and regulatory requirements.